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Q  Which SSRIs most effectively 
treat depression in adolescents?
 We don’t know which selective 
 serotonin reuptake inhibitors 
(SSRIs) are the most effective and safe be-
cause no studies have compared these an-
tidepressants with each other. 
Three SSRI antidepressant medica-
tions—fluoxetine, sertraline, and escita-
lopram—produce modest improvements 
(about 5% to 10%) in standardized depres-
sion scores without a significant increase 
in the risk of suicide-related outcomes 
(suicidal behavior or ideation) in adoles-
cent patients with major depression of 
moderate severity. As a group, however, 
the newer-generation antidepressants, 
including SSRIs, increase suicide-related 
outcomes by 50%. Citalopram, paroxetine, 
venlafaxine, and mirtazapine don’t im-
prove depression scores (strength of rec-
ommendation [SOR]: A, meta-analyses of 
randomized controlled trials [RCTs]). 
An updated national guideline rec-
ommends specific psychological therapy 
for adolescents with mild depression and 
combined psychotherapy and fluoxetine 
for moderate or severe depression, with 
sertraline or citalopram as second-line 
agents (SOR: A, RCTs).
Evidence summary
A Cochrane systematic review (19 RCTs; 
3335 patients, total) of newer-generation an-
tidepressants for treating depression in ado-
lescents found that, overall, they produced 
both a small decrease in symptom sever-
ity scores and an increased risk of suicide- 
related outcomes.1 
Three SSRIs slightly lower  
one symptom severity score 
Investigators performed a meta-analysis of 
all trials (14 RCTs; 2490 patients, total) that 
used the same standardized symptom se-
verity score (the Children’s Depression Rat-
ing Scale—Revised [CDRS-R], range 17 to 
113 points) to evaluate the following medi-
cations: fluoxetine, sertraline, escitalopram, 
citalopram, paroxetine, venlafaxine, and 
mirtazapine.1 
All participants were outpatients who 
met criteria for a primary diagnosis of major 
depression, excluding comorbid conditions. 
The CDRS-R scores were evaluated by clini-
cians; the mean baseline score was 57 (40 is 
considered a threshold score for diagnosis, 
and above 60 indicates severe symptoms). 
Only 5 trials reported patients’ self-rated 
depression symptom severity (in patients 
taking fluoxetine and paroxetine) and none 
reported improvement. Treatment courses 
ranged from 8 to 12 weeks.
As a group, the newer antidepressants 
slightly reduced CDRS-R scores in adoles-
cents (by 4.21 points, 95% confidence interval 
[CI], 0.41-5.95) but increased suicide-related 
outcomes (relative risk [RR]=1.47; 95% CI, 
0.99-2.19). The individual antidepressants 
fluoxetine, sertraline, and escitalopram each 
produced statistically significant but clini-
cally small reductions in CDRS-R scores of 
5% to 10% without significantly increasing 
suicide-related outcomes (TABLE1). The other 
medications evaluated individually didn’t 
improve CDRS-R scores, and only venlafax-
ine increased suicide-related outcomes.
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Other symptom severity scores  
show no improvement with SSRIs
Five additional RCTs not included in the 
meta-analysis that used standardized symp-
tom severity scores other than the CDRS-R 
(Schedule for Affective Disorders and Schizo-
phrenia for School-Aged Children [K-SADS], 
Montgomery-Asberg Depression Rating 
Scale [MADR], and Hamilton Depression 
Rating Scale [HAM-D]) found no improve-
ment with fluoxetine (2 RCTs; 63 patients, 
total), citalopram (one RCT, 233 patients), or 
paroxetine (2 RCTs; 466 patients, total).
Certain drugs cause significantly more  
adverse events than placebo 
Ten RCTs evaluated adverse events in adoles-
cents treated with fluoxetine, escitalopram, 
citalopram, and paroxetine and reported a 
small increase over placebo when all medi-
cations were combined as a group (RR=1.11; 
95% CI, 1.05-1.17). Investigators reported that 
TABLE
Efficacy and safety of newer antidepressants in adolescents1
Antidepressant/
dose range
Type of studies 
and duration
Number of 
patients
Mean age/
age range 
(years)
CDRS-R 
baseline 
score(s)*
Reduction in  
CDRS-R vs 
placebo 
(95% CI)
RR of suicide-
related outcomes 
vs placebo† 
(95% CI)
Adverse effects 
significantly 
more likely vs 
placebo
Fluoxetine 
20-40 mg/d
Meta-analysis 
of 3 RCTs, 
8-12 wk
754 12.2-14.6 58 5.63**  
(3.86-7.39)
1.77 
(0.85-3.69)
Headaches 
Sertraline 
25-200 mg/d
Meta-analysis 
of 2 RCTs, 
10 wk
364 6-17 64 3.52**  
(0.04-6.64)
2.97 
(0.61-14.52)
Escitalopram 
10-20 mg/d
Meta-analysis 
of 2 RCTs, 
8 wk
565 12.2-14.7 56 2.67**  
(0.48-4.85)
0.91 
(0.47-1.76)
Abdominal 
pain, nausea, 
vomiting,  
dizziness 
Citalopram 
20-40 mg/d
RCT, 8 wk 178 12.1 59 2.90  
(-1.97 to 7.77)
1.53 
(0.55-4.27)
Paroxetine 
10-50 mg/d
Meta-analysis 
of 2 RCTs, 8 wk
259 12-14.6 58 and 
61
1.18  
(-3.92 to 6.29)
1.57 
(0.46-5.31)
Venlafaxine 
37.5-225 mg/d
Meta-analysis 
of 2 RCTs, 8 wk
334 12-14.6 56 1.18  
(-3.92 to 6.29)
12.93** 
(1.71-97.82)
Abdominal 
pain and  
dizziness 
Mirtazapine 
15-45 mg/d
Meta-analysis 
of 2 RCTs, 8 wk
265 12.3 51 and 
59
2.79  
(-0.83 to 6.42)
0.50 
(0.03-7.90)
Weight gain, 
headaches, 
hypertriglyc-
eridemia, 
somnolence, 
urticaria
CDRS-R, Children’s Depression Rating Scale-Revised; CI, confidence interval; RCTs, randomized controlled trials; RR, relative risk.
*Threshold for diagnosis of major depression=40. Scores >60 indicate severe symptoms.
**Outcome was statistically significant.
†Suicide-related outcomes include suicide-related behavior and suicidal ideation.
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the individual antidepressants fluoxetine, 
escitalopram, venlafaxine, and mirtazapine 
produced significantly more adverse events 
than placebo (P values not given). No stud-
ies compared antidepressant medications 
against each other for either efficacy or 
potential harms.
Recommendations
A newly revised expert guideline recom- 
mends treating mildly depressed adoles-
cents with a specific psychological ther- 
apy—individual cognitive behavioral ther- 
apy, interpersonal therapy, family therapy, or 
psychodynamic psychotherapy—for at least 
3 months.2 
For adolescents with moderate to severe 
depression, the guideline advocates psycho-
therapy with the option of adding fluoxetine, 
although using antidepressants in adoles-
cents who haven’t at least tried psychotherapy 
is outside of the drug’s indications. 
The guideline also recommends care-
ful monitoring for adverse effects and close 
review of mental state—weekly for the first 
4 weeks of treatment, for example. If fluox-
etine doesn’t help, sertraline and citalopram 
are recommended as alternatives.                JFP
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